Bristol Myers lifts sales outlook as newer drugs drive growth
Bristol Myers Squibb (BMY) raised its 2026 revenue forecast to $49.75B-$50.25B, up from $50B, after Q3 results beat expectations. Non-GAAP EPS guidance updated to $6.35-$6.55. Q3 revenue rose 7.2% YoY to $13.1B, with Growth Portfolio sales up 12% to $7.7B, driven by newer drugs like Opdivo Qvantig.
How this was made
The 30-second read
Why it matters
The guidance raise signals management confidence in newer oncology growth (notably Opdivo Qvantig) and provides fresh 2026 revenue and EPS ranges that can drive re-rating.
Market read
Fresh 2026 guidance and product-level growth details create a direct catalyst for BMY positioning versus patent-expiration concerns.
What to watch
The article cites acquired in-process R&D and licensing income in EPS guidance; traders may want to separate underlying operating momentum from one-time or non-core items.
Background
Bristol Myers is shifting mix toward newer medicines to mitigate revenue pressure as blockbuster Eliquis approaches patent expiration.
Ticker impact
Bristol Myers raised its 2026 revenue forecast and updated non-GAAP EPS guidance after Q3 results beat expectations, led by Opdivo Qvantig growth.
Likely upward bias as the market reprices 2026 growth durability from newer drugs versus looming Eliquis generic pressure.
The article provides specific, company-issued forecast ranges for revenue and non-GAAP EPS, plus product-level growth (Opdivo Qvantig and Growth Portfolio) that explains the upgrade.
Market effects
Reinforces the oncology large-cap narrative that newer formulations can offset patent-loss risk, potentially supporting peer sentiment around pipeline execution.
Limited direct regional spillover; primarily a US pharma earnings and guidance read-through.
Modest global relevance, as the driver is company-specific oncology product performance and US patent-timing risk.
Counterpoint
The upgrade may be partially offset by accelerating Eliquis generic competition risk, so upside could fade if newer-drug growth does not scale enough to fully replace legacy declines.
Key entities
- companyBristol Myers Squibb
US-listed drugmaker raising 2026 revenue and non-GAAP EPS guidance after Q3 beat, led by newer oncology medicines.
- productOpdivo Qvantig
Injectable alternative cited as a key growth driver, with quarterly sales reported at $334M.
- productEliquis
Blockbuster anticoagulant flagged for potential US generic competition in 2028, a key medium-term risk.
